OverviewSuggest Edit
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow creating humanized antibodies that can be used either alone in unlabeled or naked form or conjugated with radioactive isotopes, chemotherapeutics, cytokines, or toxins.
| Type | Public | |
| Founded | 1982 | |
| HQ | Morris Plains, US | Map |
| Website | immunomedics.com | |
| Employee Ratings | More |
Key People/Management at Immunomedics
Behzad Aghazadeh
Executive Chairman of the Board of Directors
Usama Malik
Chief Financial Officer, Chief Business Officer
Brendan Delaney
Chief Commercial Officer
Kurt Andrews
Chief Human Resources Officer
Jared Freedberg
General Counsel and Corporate Secretary
Bryan Ball
Chief Quality Officer
Immunomedics Office Locations
Immunomedics has offices in Morris Plains and Rödermark
Morris Plains, US (HQ)
300 The American Rd
Rödermark, DE
Paul-Ehrlich-Straße 22/D1
Immunomedics Financials and Metrics
Immunomedics Revenue
Immunomedics's revenue was reported to be $295 k in FY, 2019 which is a 86.3% decrease from the previous period.
| USD | |
|---|---|
Revenue (Q2, 2020) | 20.1m |
Gross profit (Q2, 2020) | 18.4m |
Gross profit margin (Q2, 2020), % | 91.7% |
Net income (Q2, 2020) | (66.5m) |
EBIT (Q2, 2020) | (53.0m) |
Market capitalization (17-Sept-2020) | 19.7b |
Closing stock price (17-Sept-2020) | 85.3 |
Cash (30-Jun-2020) | 971.2m |
EV | 18.8b |
Immunomedics's current market capitalization is $19.7 b.
Annual
Half Year
| USD | H2, 2018 |
|---|---|
Sales and marketing expense | 19.8m |
Annual
Annual
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 23.6k |
Debt/Equity | -3.2 x |
Debt/Assets | 1.2 x |
Financial Leverage | -2.7 x |
Immunomedics Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| IBC Pharmaceuticals, Inc. | ||
| Immunomedics GmbH |
Immunomedics Cybersecurity Score
Immunomedics Revenue Breakdown
Immunomedics revenue breakdown by business segment: 69.6% from Product sales, 15.3% from License fee and other revenues and 15.1% from Research and development
Immunomedics Online and Social Media Presence
Immunomedics's Trends
Immunomedics News and Updates
September 14, 2020
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout
WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Immunomedics, Inc. (“Immunomedics”) (NASDAQ GS: IMMU) regarding possible breaches of fiduciary duties and other violations of law related to Immunomedics’ agreement to be acquired by …
September 13, 2020
Gilead to buy cancer drugmaker Immunomedics in $21 billion deal
The deal will provide Gilead access to Immunomedics' cancer treatment drug called Trodelvy, an FDA-approved treatment for metastatic triple-negative breast cancer.
September 09, 2020
Immunomedics Announces Key Oral Presentations at ESMO 2020
Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the presentation of five abstracts at ESMO Virtual Congress 2020, highlighted by oral presentations of the ASCENT study in metastatic tri…
September 02, 2020
Immunomedics to Participate in Upcoming Healthcare Conferences
Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferenc…
August 20, 2020
(IMMU) Alert: Shareholder Class Action Against Immunomedics Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel
SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Immunomedics Inc. (NASDAQ: IMMU) ("Immunomedics" or the "Company") against certain of its officers and directors. Specifically, a class-action lawsuit pending in the United States...
August 17, 2020
Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer of Trodelvy
Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for Samsung Biologics to produce …
Immunomedics Blogs
May 27, 2020
Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19
The post Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19 appeared first on Immunomedics.
May 13, 2020
Immunomedics to Present New Trodelvy Data in Non-Breast Indications at the 2020 ASCO Virtual Meeting
The post Immunomedics to Present New Trodelvy Data in Non-Breast Indications at the 2020 ASCO Virtual Meeting appeared first on Immunomedics.
May 07, 2020
Immunomedics to Participate in BofA Securities 2020 Healthcare Conference
The post Immunomedics to Participate in BofA Securities 2020 Healthcare Conference appeared first on Immunomedics.
May 06, 2020
Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update
The post Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update appeared first on Immunomedics.
May 04, 2020
Immunomedics Announces Commercial Availability of Trodelvy in the United States
The post Immunomedics Announces Commercial Availability of Trodelvy in the United States appeared first on Immunomedics.
April 30, 2020
Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast on May 6, 2020
The post Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast on May 6, 2020 appeared first on Immunomedics.
Immunomedics Frequently Asked Questions
When was Immunomedics founded?
Immunomedics was founded in 1982.
Who are Immunomedics key executives?
Immunomedics's key executives are Behzad Aghazadeh, Usama Malik and Brendan Delaney.
How many employees does Immunomedics have?
Immunomedics has 366 employees.
What is Immunomedics revenue?
Latest Immunomedics annual revenue is $295 k.
What is Immunomedics revenue per employee?
Latest Immunomedics revenue per employee is $806 .
Who are Immunomedics competitors?
Competitors of Immunomedics include Novartis, ImmunoGen and AstraZeneca.
Where is Immunomedics headquarters?
Immunomedics headquarters is located at 300 The American Rd, Morris Plains.
Where are Immunomedics offices?
Immunomedics has offices in Morris Plains and Rödermark.
How many offices does Immunomedics have?
Immunomedics has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies